Sunnyvale, CA 2/15/07—Cepheid, a provider of nucleic acid amplification equipment and reagents, has acquired Sangtec Molecular Diagnostics AB from ALTANA Pharma AG for $27 million in cash. Based in Broma, Sweden, Sangtec is a manufactuer of PCR-based molecular diagnostics products and had 2006 revenues of $8 million. Cepheid intends to integrate Sangtec’s affigene kits for […]
The FDA plans to define the term “gluten-free” for the purposes of food labeling. The FDA has produced a draft proposal in January and is accepting comments on the proposal until April. According to the FDA, a gluten-free food does not contain wheat, rye or barley; it also should not contain any ingredient made from […]
Company Announcements CETAC Technology entered into a marketing and partnership agreement with Coherent for its GeoLasPro Laser Ablation System in fall 2006. CETAC Technology named StarLab SaS as its Italian distributor in fall 2006. PANalytical, a Spectris company, opened a direct sales and support organization in Mexico in November 2006. The employees of PONA, the […]
South Korea’s economy is expected to grow by 4.5% this year, down from 5% last year. Last year, approximately 300,000 new jobs were created in the country, falling short of a goal of 350,000 jobs. To increase the number of jobs, ramp up investments and spur R&D activities, government will partner with the industry. The […]
Grand Rapids, MI 2/8/07; Amersham, UK 2/8/07—Halma has acquired X-Rite’s Labsphere business for $13.9 million in cash and a deferred cash consideration of $1.5 million. Labsphere is a designer and manufacturer of light testing and measurement products, as well as specialized optical coatings. The company posted 2006 revenues of $12.5 million and an operating profit […]
According to the FDA, 10% of drugs in the world are counterfeit. The World Health Organization (WHO) takes a more nuanced view: according to the organization, less than 1% of drugs in developed nations are counterfeit, but 10% of drugs in developing economies are counterfeit. However, in parts of Latin America, Southeast Asia and sub-Saharan […]
While President Bush’s proposed budget for FY08 would increase the total federal R&D investment by 1.4% to $143.0 billion, federal support of basic and applied research would decline to $55.4 billion, a 2% drop from the FY07 budget. Not including NASA, the total budget increase for nondefense R&D agencies is only 0.8%, below the national […]
At the third annual meeting of the Strategic Council for the Health Industry (CSIS), members of the government and leaders in the French health industry discussed methods to boost R&D spending and create more jobs. One goal of the CSIS is to increase the amount spent on R&D in the health industry by 10% over […]
Between 2000 and 2005, the Chinese biopharmaceutical sector grew 30%, while the global average for the sector grew 19%. Nonetheless, some observers are concerned that production will slow over the next five years. The fastest-growing Chinese biopharmaceutical manufacturers have concentrated on using genetically modified microorganisms to express proteins and very few are developing the capacity […]
Major restructurings of R&D operations were announced earlier this year by two of the world’s largest pharmaceutical companies, Pfizer and Roche. Such announcements are becoming more common for so-called “big pharma” (see IBO 4/15/05, 4/15/06), as many of the world’s 10 largest drug firms struggle to maintain historical levels of profitability during a period of […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
